Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 2,913 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Event Clear all

Conditions: Hepatocellular Carcinoma
Interventions: Livmoniplimab, Budigalimab, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Duarte, California • Irvine, California • Orange, California + 9 more

Conditions: Ovarian Cancer
Interventions: Mirvetuximab Soravtansine, Bevacizumab, Carboplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 31
States / cities: La Jolla, California • Solvang, California • Gainesville, Florida + 28 more

Conditions: Breast Cancer
Interventions: Research Cardiac MRI, Biomarkers; Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Alzheimer's Disease
Interventions: Timed Planned Activity, Home Safety and Education Program; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years to 100 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cardiovascular Disease
Interventions: AZD0780, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 15,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 357
States / cities: Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 284 more

Conditions: Inflammatory Bowel Disease (IBD)
Interventions: Gut Microbial Transplantation; Drug
Lead sponsor: Corewell Health West; Other
Eligibility: 7 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions
Interventions: Denosumab, Zoledronic acid, Placebo to Denosumab, Placebo to zoledronic acid, Denosumab (for the open-label treatment phase); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 1,718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 79
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 67 more

Conditions: SARS-CoV-2
Interventions: SPIKEVAX; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: Not listed
Enrollment: 15,196,685 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza
Interventions: Personal Protective Equipment (PPE) - Under High Air Hygiene, No Intervention - Under High Air Hygiene, Personal Protective Equipment (PPE) - Under Low Air Hygiene, No Intervention - Under Low Air Hygiene; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 59 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • College Park, Maryland

Conditions: Advanced Non-small Cell Lung Cancer
Interventions: Atezolizumab; Drug
Lead sponsor: Liza Villaruz, MD; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Orlando, Florida • Pittsburgh, Pennsylvania

Conditions: Malignant Peripheral Nerve Sheath Tumors (MPNST)
Interventions: ASTX727; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Breast Cancer, Triple Negative Breast Cancer
Interventions: Talazoparib, Atezolizumab, Radiation; Drug · Radiation
Lead sponsor: Mylin A. Torres, MD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Birmingham, Alabama • Atlanta, Georgia

Conditions: Hospital Acquired Condition
Interventions: The Beat Analytics System (BAS); Device
Lead sponsor: Bob Topp; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions: Deutetrabenazine Oral Capsule; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: T2DM (Type 2 Diabetes Mellitus)
Interventions: Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801; Drug
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Ulcerative Colitis
Interventions: ABBV-668; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 18
States / cities: Chula Vista, California • Maitland, Florida • Margate, Florida + 13 more

Conditions: Overweight and Obesity
Interventions: Episodic Future Thinking Group; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 10 Years to 14 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Infection
Interventions: Transperineal MRI-guided prostate biopsy, Transrectal MRI-guided prostate biopsy, Antibiotic (prophylaxis); Procedure · Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 16
States / cities: Los Angeles, California • Farmington, Connecticut • Washington D.C., District of Columbia + 11 more

Conditions: Coronary Artery Disease, Sleep Disorder; Breathing-Related, Sleep Disorder; Insomnia Type
Interventions: Polysomnograpy, actigraphy; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Mock Code Training Simulation
Interventions: Accessing Confidence levels of Nursing students; Behavioral
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Intra-Articular or Extra-Articular Distal Humerus Fracture, Distal Humerus Fracture
Interventions: LORRAINE 2.5/3.5 mm Distal Humerus System; Device
Lead sponsor: Bonebridge AG; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ideomotor Apraxia
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 21 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Conjunctivitis, Atopic Dermatitis
Interventions: dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Irvine, California • Palo Alto, California • Pasadena, California + 12 more

Conditions: Chronic Granulomatous Disease
Interventions: Administration of drug (Interferon-gamma 1-b) subcutaneously; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Pilot Study of Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy

Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

DMID 21-0041; Influenza CVD 59000

Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)

A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer

The Effect of Real Time Analytics on Adverse Events Among Hospitalized Patients

Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

Episodic Future Thinking and Weight-Loss

PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2

Comorbid Insomnia and Sleep Disordered Breathing in Patients Undergoing Cardiac Rehabilitation

Performance Improvement: Does Mock Code Simulation Improve the Confidence Level of Newly Graduated Nurses?

Clinical Outcomes After Treatment of Distal Humerus Fractures With the LORRAINE 2.5/3.5 mm Distal Humerus System

Using fMRI to Understand the Roles of Brain Areas for Fine Hand Movements

Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis

Effect of IFN-γ on Innate Immune Cells